Novo Nordisk and Eli Lilly are still duking it out in the weight loss drug arena. Zepbound's been eating into Wegovy's slice of the pie lately. But the winds might be changing.
Here's the thing: Novo Nordisk's cooking up an oral version of Wegovy. Game-changer? Maybe. Pills are just easier than shots, right?
The numbers look pretty good for Novo. Their oral Wegovy seems to pack more punch than Lilly's pill-in-progress. We're talking 15.1% vs 12.4% weight loss. Not too shabby.
Novo's already knocked on the FDA's door. They're waiting for an answer, probably in late 2025. If it's a green light,
Here's the thing: Novo Nordisk's cooking up an oral version of Wegovy. Game-changer? Maybe. Pills are just easier than shots, right?
The numbers look pretty good for Novo. Their oral Wegovy seems to pack more punch than Lilly's pill-in-progress. We're talking 15.1% vs 12.4% weight loss. Not too shabby.
Novo's already knocked on the FDA's door. They're waiting for an answer, probably in late 2025. If it's a green light,